Astellas wins approval for menopause hot flash treatment Veozah
Astellas has won approval for its nonhormonal hot flash treatment, after hitting a delay earlier this year.
The FDA cleared a 45 mg daily dose of fezolinetant, now marketed as Veozah, to treat moderate to severe vasomotor symptoms (VMS), the technical term behind hot flashes, due to menopause. While up to 80% of women will experience hot flashes in their lifetimes, about 70% go untreated, Astellas said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
